208 related articles for article (PubMed ID: 29463178)
1. Interim FDG-PET/CT in Hodgkin lymphoma: what are we actually looking at?
Adams HJA; Kwee TC
Acta Oncol; 2018 Aug; 57(8):1128-1130. PubMed ID: 29463178
[No Abstract] [Full Text] [Related]
2. Measurement uncertainty and clinical impact of target-to-background ratios derived by interim FDG-PET/CT in Hodgkin lymphoma: reply to Laffon and Martan.
Annunziata S; Calcagni ML; Indovina L; Rufini V
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2140-2141. PubMed ID: 28879394
[No Abstract] [Full Text] [Related]
3. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
4. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
5. Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma.
Adams HJA; Kwee TC
Br J Haematol; 2018 Oct; 183(1):129-131. PubMed ID: 28905368
[No Abstract] [Full Text] [Related]
6. Incidental Detection of a Hodgkin Lymphoma on 18F-Choline PET/CT and Comparison With 18FDG PET/CT in a Patient With Prostate Cancer: Reply.
Goineau A; Supiot S
Clin Nucl Med; 2016 Sep; 41(9):746-7. PubMed ID: 27088390
[No Abstract] [Full Text] [Related]
7. [FDG PET/CT and childhood Hodgkin lymphoma].
Montravers F; Kerrou K; Huchet V; Pascal O; Talbot JN
Arch Pediatr; 2009 Jun; 16(6):669-71. PubMed ID: 19541124
[No Abstract] [Full Text] [Related]
8. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
[TBL] [Abstract][Full Text] [Related]
9. Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma: response to Adams and Kwee.
Dann EJ; Paltiel O
Br J Haematol; 2018 Oct; 183(1):131-133. PubMed ID: 28832981
[No Abstract] [Full Text] [Related]
10. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
11. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
12. Role of FDG PET-CT in the treatment management of Hodgkin lymphoma.
Berriolo-Riedinger A; Becker S; Casasnovas O; Vander Borght T; Édeline V
Cancer Radiother; 2018 Sep; 22(5):393-400. PubMed ID: 30033076
[TBL] [Abstract][Full Text] [Related]
13. Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations?
Adams HJA; Kwee TC
Br J Haematol; 2018 Apr; 181(1):122-123. PubMed ID: 28025838
[No Abstract] [Full Text] [Related]
14. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
Hutchings M
Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
[TBL] [Abstract][Full Text] [Related]
15. [Update on the use of FDG-PET/CT in malignant lymphoma].
Terauchi T
Rinsho Ketsueki; 2016; 57(10):2008-2012. PubMed ID: 27795508
[TBL] [Abstract][Full Text] [Related]
16. Cat-Scratch Disease: A Pitfall for Lymphoma Evaluation by FDG-PET/CT.
Dubreuil J; Dony A; Salles G; Traverse-Glehen A; Giammarile F; Skanjeti A
Clin Nucl Med; 2017 Feb; 42(2):106-107. PubMed ID: 27997427
[TBL] [Abstract][Full Text] [Related]
17. Neither Posttreatment PET/CT Nor Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma.
Adams HJ; Kwee TC
J Nucl Med; 2017 Apr; 58(4):684-685. PubMed ID: 28373395
[No Abstract] [Full Text] [Related]
18. PET/CT: appropriate application in lymphoma.
Wang X
Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
[TBL] [Abstract][Full Text] [Related]
19. Reply: Neither Posttreatment PET/CT Nor Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma.
Bhethanabhotla S; Bakhshi S
J Nucl Med; 2017 Apr; 58(4):685-686. PubMed ID: 27932560
[No Abstract] [Full Text] [Related]
20. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma.
Tirumani SH; LaCasce AS; Jacene HA
PET Clin; 2015 Apr; 10(2):207-25. PubMed ID: 25829087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
